

Supplementary Table 2. Types of treatment during restricted and unrestricted DAA era

Types of treatment	Value
Restricted DAA era (n=320)	
Pegylated interferon + ribavirin	185 (57.8)
Ombitasvir/paritaprevir/ritonavir ± ribavirin	66 (20.6)
Sofosbuvir daclatasvir + ribavirin	42 (13.1)
Sofosbuvir/velpatasvir ± ribavirin	20 (6.3)
Sofosbuvir/ledipasvir ± ribavirin	4 (1.3)
Glecaprevir/pibrentasvir	1 (0.3)
Sofosbuvir + pegylated interferon + ribavirin	2 (0.6)
Unrestricted DAA era (n=681)	
Pegylated interferon + ribavirin	34 (4.7)
Ombitasvir/paritaprevir/ritonavir ± ribavirin	3 (0.4)
Sofosbuvir/velpatasvir ± ribavirin	643 (94.4)
Sofosbuvir/ledipasvir ± ribavirin	1 (0.5)

Values are presented as number (%).
DAA, direct acting antiviral.